Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) developed to address excess visceral abdominal fat, particularly in people living with HIV. Unlike direct growth hormone replacement, it stimulates the pituitary to produce growth hormone in a more natural, pulsatile pattern Metabolic effects of a growth hormone-releasing factor in patients with HIV+1. The FDA approved it for reducing excess abdominal fat in HIV-associated lipodystrophy, based on multiple randomized trials showing significant reductions in visceral adipose tissue (VAT) and waist circumference Metabolic effects of a growth hormone-releasing factor in patients with HIV+2.

The compound emerged from research into HIV-related body shape changes, where some antiretroviral therapies led to central fat accumulation while limbs remained lean. Tesamorelin was studied in pivotal phase 3 trials starting in 2007, demonstrating a 10–15% VAT reduction over 26 weeks without substantial changes in body weight Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data+1. Subsequent work extended its investigation to liver fat reduction in HIV-associated fatty liver disease (NAFLD/MASLD) and, more recently, to body composition in people on modern integrase inhibitor regimens Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation+2. Its utility is most pronounced in individuals with disproportionate visceral adiposity and relatively normal BMI, where it repartitions fat rather than causing generalized weight loss Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+1.

Tesamorelin works by binding to the GHRH receptor on the pituitary gland, a G protein-coupled receptor that activates cAMP signaling and stimulates the somatotroph cells to release growth hormone in pulses Tesamorelin improves fat quality independent of changes in fat quantity+2. This preserves the body's natural feedback loops that normally regulate the growth hormone/IGF-1 axis, unlike administering synthetic growth hormone directly Tesamorelin improves fat quality independent of changes in fat quantity+2. The resulting increase in circulating growth hormone and IGF-1 triggers metabolic effects that preferentially break down visceral fat stores while sparing subcutaneous fat in the limbs Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data+1.

A key clinical consequence is a reduction in visceral adipose tissue (VAT) measured by CT or MRI, along with decreases in waist circumference and trunk fat, even when total body weight changes little Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data+1. This selectivity is attributed to the more physiological, pulsatile growth hormone pattern, which appears to target the metabolically active visceral fat depot more effectively than continuous exposure would Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data+1. In the liver, increased growth hormone signaling suppresses new fat synthesis and promotes fat oxidation, leading to reductions in liver fat in people with HIV-associated steatotic liver disease Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial+1. Beyond the liver, secondary analyses show improvements in adipose tissue quality, with fat cells becoming smaller and denser in responders Tesamorelin improves fat quality independent of changes in fat quantity. While there is preclinical evidence of extra-pituitary GHRH actions on inflammation and tissue repair, these effects are not yet the basis for clinical use Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity+2.

The primary documented effect in HIV-associated lipodystrophy is a reduction in visceral adipose tissue (VAT) by approximately 27.7 cm² on average, accompanied by decreases in trunk fat (1.18 kg), waist circumference (1.61 cm), and liver fat (4.28%), while lean body mass increases by about 1.42 kg (community protocol). These changes occur without significant changes in overall BMI or subcutaneous fat, underscoring a redistribution effect rather than simple weight loss Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+1. In responders, CT scans also show improved fat quality, with higher density of both VAT and subcutaneous fat, suggesting smaller, healthier adipocytes (community protocol).

For liver health, randomized trials demonstrate that Tesamorelin reduces hepatic fat fraction and slows or prevents fibrosis progression over 12 months in HIV-associated NAFLD/MASLD, though complete reversal of fibrosis is not well established Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial+1. Transcriptomic studies link these benefits to reduced inflammatory and fibrogenic signals, including decreases in VEGFA, TGFB1, and CSF1 Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Metabolic effects are monitored closely. While Tesamorelin increases IGF-1 predictably, studies in type 2 diabetes show it does not cause major glucose deterioration in the aggregate, but some individuals may experience hyperglycemia Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1. In a trial of people with HIV and neurocognitive impairment, Tesamorelin did not produce a cognitive benefit over standard care, despite reducing waist circumference Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. Thus, its effects are most robust for body composition and liver endpoints, with weaker evidence for brain or metabolic improvements.

Research protocols for Tesamorelin consistently use a fixed dose of 2 mg administered subcutaneously once daily, typically into the abdominal area Metabolic effects of a growth hormone-releasing factor in patients with HIV+2. The landmark phase 3 trials spanned 26 weeks, with many participants continuing into a 52-week extension, and these durations remain the best-evidenced for meaningful visceral fat reduction Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+1. For HIV-associated liver fat, protocols extend to 12 months, showing progressive improvements in hepatic steatosis Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial+1. No weight-based dosing adjustment is required, as the fixed dose was effective across body weights studied Metabolic effects of a growth hormone-releasing factor in patients with HIV+1.

If using vials that require reconstitution, the goal is to deliver 2 mg in a convenient volume. Common community practices involve dissolving a vial to a concentration of 2 mg/mL or higher, then injecting the corresponding volume (e.g., 1 mL for 2 mg at 2 mg/mL). An interactive calculator elsewhere on this page can help determine exact volumes. Dosing is usually performed at a consistent time each day; some protocols align administration with the evening to mimic the natural nocturnal surge in growth hormone, though no strict timing requirement comes from the trials Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. Missed doses are generally compensated by resuming the next day without doubling up.

Response is judged by reductions in waist circumference and, if available, imaging of VAT or liver fat, rather than by scale weight. Many users monitor waist girth monthly and reassess labs (IGF-1, glucose, lipids) at weeks 6-12 and 26 Metabolic effects of a growth hormone-releasing factor in patients with HIV+1. Short cycles of 8-12 weeks are common in community practice but lack the sustained efficacy profile of longer protocols Metabolic effects of a growth hormone-releasing factor in patients with HIV+1.

Tesamorelin is supplied as a lyophilized powder that must be reconstituted with a sterile diluent, typically bacteriostatic water for multi-dose vials or sterile water for single-use handling Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension. The process involves slowly injecting the diluent down the vial wall, then gently swirling (never shaking) to dissolve the powder, as vigorous agitation can damage the peptide Metabolic effects of a growth hormone-releasing factor in patients with HIV. Once mixed, the solution should be stored in the refrigerator (2–8°C) and used within 21–28 days if bacteriostatic water was used, or within 7–14 days with sterile water Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension.

Standard clinical formulations deliver 2 mg in a 2 mL volume (older formulation). A more concentrated formulation (1.28 mg in 0.16 mL) has been shown bioequivalent to the original 2 mg dose P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants. The concentrated form reduces injection discomfort without altering systemic exposure P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants. For research vials where the user determines the concentration, the goal is to prepare a solution that allows precise delivery of 2 mg. The interactive calculator provided on this page will compute the exact volumes based on your vial size and desired concentration, so you do not need to perform the math manually. Simply input the total milligrams in your vial and the amount of diluent added.

Key handling tips: protect the unreconstituted vial from heat and light; store in the refrigerator or freezer until use. After reconstitution, keep the solution cold and discard if it becomes cloudy or particulate. Rotate injection sites on the abdomen to reduce local irritation Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+1.

Formal drug interaction studies show Tesamorelin has minimal impact on CYP3A-mediated metabolism. Co-administering it with simvastatin or ritonavir did not alter drug exposure to a clinically meaningful degree, so no dose adjustments are needed for these agents Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Its compatibility with modern antiretroviral regimens is further supported by a trial in people on integrase inhibitors, where efficacy and tolerability were preserved without excess glycemic issues Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

However, pharmacodynamic interactions are a greater concern. Because Tesamorelin amplifies the growth hormone/IGF-1 axis, combining it with other GH-related compounds (recombinant GH, IGF-1 analogs, or other secretagogues like CJC-1295 or MK-677) can lead to excessive IGF-1, fluid retention, joint pain, and increased risk of carpal tunnel syndrome Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1. Such stacks are generally avoided outside specialist protocols. Conversely, pairing Tesamorelin with GLP-1 receptor agonists (e.g., semaglutide) may be complementary: GLP-1s promote overall weight loss while Tesamorelin specifically targets visceral fat, a strategy being explored in HIV populations with mixed obesity and lipodystrophy Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists+1. Glucose-lowering medications require monitoring, as Tesamorelin can influence insulin sensitivity; check fasting glucose and HbA1c when using insulin, sulfonylureas, or other antidiabetic drugs Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Hormonal supplements, including testosterone and DHEA, can add to fluid retention and metabolic complexity, so stacking demands extra vigilance Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation+1. For athletes, Tesamorelin is prohibited by WADA and is detectable in urine, creating a testing interaction rather than a biological one Analysis of seized peptide and protein‐based doping agents using four complimentary methods: Liquid chromatography coupled with time of flight mass spectrometry, liquid chromatography–ultraviolet, Bradford, and immunoassays+2.

Research trials used Tesamorelin continuously for 26 to 52 weeks, and benefits on visceral fat and liver fat were maintained only while treatment continued. Once stopped, visceral fat tended to reaccumulate, indicating that cycling on and off is not supported by efficacy data for sustained fat reduction Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+2. Nevertheless, many community protocols adopt cycles of 12–24 weeks on, followed by a 4–8 week break, primarily to manage side effects, cost, or to reassess whether the treatment is still working Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data+1.

The most common reasons for cycling include rising IGF-1 levels, onset of joint pain, fluid retention, or paresthesias (tingling), which can signal overstimulation of the GH axis Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1. A break allows these symptoms to subside and permits bloodwork (IGF-1, glucose) to return to baseline. Some long-term users schedule a reassessment at the 6-month mark: if waist circumference or imaging show a plateau, a washout period may restore responsiveness upon reintroduction, though this is speculative Metabolic effects of a growth hormone-releasing factor in patients with HIV+1. A more structured approach is continuous treatment with periodic monitoring every 3-6 months, stopping only if adverse effects or lab values exceed thresholds.

Signs that a break may be needed include: persistent IGF-1 above the age-adjusted range, new or worsening carpal tunnel symptoms, steady increase in fasting glucose, or a halt in central fat loss for over 6-8 weeks Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1. Whatever the pattern, any planned interruption should consider the likelihood of visceral fat regain and have a clear monitoring plan in place Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+1.

Stacking Tesamorelin with other compounds is an area of growing interest, particularly in multi-target body composition strategies. The most evidence-supported stack is with GLP-1 receptor agonists (such as semaglutide or tirzepatide), where the GLP-1 component drives overall weight loss while Tesamorelin specifically tackles visceral fat Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists+1. This combination is being considered for HIV patients who have both generalized obesity and central adiposity, and early case reports describe complementary effects, though careful glucose monitoring is essential Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.

Other common stacks include regenerative peptides like BPC-157 or TB-500 for injury healing, though no formal interaction data exist and the add-on benefit over Tesamorelin alone for soft tissue repair is unproven Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Stacking with other growth hormone secretagogues (CJC-1295, ipamorelin, MK-677) is generally discouraged because it redundantly overstimulates the GH/IGF-1 axis, increasing side effects without clear additive fat-loss benefits Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults+1. Similarly, combining Tesamorelin with recombinant GH or IGF-1 LR3 is considered high-risk due to fluid retention and glycemic disturbances Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1.

For those aiming to preserve muscle, Tesamorelin’s inherent lean mass increase (about 1.4 kg over 6 months) may already provide an anabolic signal; adding androgens or SARMs would further complicate insulin sensitivity and cardiovascular risk Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. In short, stacking is best limited to compounds with complementary mechanisms (like GLP-1s) and avoided with overlapping GH-axis stimulators, always under biochemical monitoring.

Tesamorelin is FDA-approved specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a status grounded in multiple phase 3 trials Metabolic effects of a growth hormone-releasing factor in patients with HIV+2. It is not approved for general obesity, athletic performance, or anti-aging, and such uses remain off-label or investigational Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1. The approved product is available as a subcutaneous injection, with newer, low-volume formulations that are bioequivalent to the original P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants. There is no record of it being a controlled substance under the DEA in the United States Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

Internationally, approval is limited; the corpus does not confirm central EMA or other major regulatory clearances, meaning access typically occurs through named-patient or special importation pathways Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. In sports, Tesamorelin is universally prohibited: WADA classifies it as a growth hormone-releasing hormone analog, and anti-doping laboratories actively screen for it in urine with validated methods Analysis of seized peptide and protein‐based doping agents using four complimentary methods: Liquid chromatography coupled with time of flight mass spectrometry, liquid chromatography–ultraviolet, Bradford, and immunoassays+2. Its presence on the prohibited list means no Therapeutic Use Exemption (TUE) is likely unless for the approved HIV indication under strict medical necessity Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications+1. For tested athletes, the detection risk is high and the substance is squarely off-limits.

The most common side effects in clinical trials mirror the physiologic effects of growth hormone excess: injection site reactions (pain, redness, bruising), joint pain (arthralgia), muscle aches (myalgia), fluid retention causing swelling, and tingling sensations (paresthesia) Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+2. These are usually mild to moderate and often improve over time or with dose adjustment. In a comparative study, a lower-volume formulation reduced injection-site pain from 19% to 12% P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants. More concerning is the potential for elevated IGF-1, which can drive many of these symptoms and, over time, increases the risk of carpal tunnel syndrome; pharmacovigilance data show a strong signal for this condition with Tesamorelin Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Metabolically, Tesamorelin can affect glucose control. While a dedicated trial in type 2 diabetes did not find a significant overall worsening in glycemic measures, individual responses vary, and hyperglycemia has been reported Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1. Therefore, monitoring fasting glucose and HbA1c is essential, especially in those with prediabetes or diabetes. Other precautions: the drug is contraindicated in active malignancy due to the theoretical risk of fueling tumor growth via IGF-1, and it should be avoided in pregnancy Tesamorelin improves fat quality independent of changes in fat quantity+1. Less common adverse effects include headache, mild gastrointestinal upset, and hypersensitivity reactions at the injection site Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial+1.

Long-term safety data beyond 52 weeks are sparse, leaving questions about sustained IGF-1 elevation on cancer risk, cardiovascular outcomes, and nerve compression syndromes Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension+2. For this reason, ongoing users are advised to reassess benefit versus side effects at regular intervals, with a low threshold to pause treatment if IGF-1 climbs too high or neuropathic symptoms appear.